Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro

Jo Ann Janovick, Shaun P Brothers, Anda Cornea, Eugene Bush, Mark T. Goulet, Wallace T. Ashton, Daryl R. Sauer, Fortuna Haviv, Jonathan Greer, P. Michael Conn

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

All reported GnRH receptor mutants (causing human hypogonadotropic hypogonadism) are misfolded proteins that cannot traffic to the plasma membrane. Pharmacoperones correct misfolding and rescue mutants, routing them to the plasma membrane where they regain function. Because pharmacoperones are often peptidomimetic antagonists, these must be removed for receptor function after rescue; in vivo this necessitates pulsatile pharmacoperone administration. As an antecedent to in vivo studies, we determined whether pharmacoperones need to be present at the time of synthesis or whether previously misfolded proteins could be refolded and rescued. Accordingly, we blocked either protein synthesis or intra-cellular transport. Biochemical and morphological studies using 12 mutants and 10 pharmacoperones representing three different chemical classes show that previously synthesized mutant proteins, retained by the quality control system (QCS), are rescued by pharmacoperones, showing that pharmacoperone administration in vivo likely need not consider whether the target protein is being synthesized at the time of drug administration.

Original languageEnglish
Pages (from-to)77-85
Number of pages9
JournalMolecular and Cellular Endocrinology
Volume272
Issue number1-2
DOIs
StatePublished - Jun 30 2007
Externally publishedYes

Fingerprint

Cell membranes
Proteins
Cell Membrane
Peptidomimetics
LHRH Receptors
Regain
Hypogonadism
Mutant Proteins
Quality Control
Quality control
Control systems
In Vitro Techniques
Pharmaceutical Preparations

Keywords

  • G protein coupled receptor
  • Hypogonadotropic hypogonadism
  • Protein folding
  • Protein trafficking

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Refolding of misfolded mutant GPCR : Post-translational pharmacoperone action in vitro. / Janovick, Jo Ann; Brothers, Shaun P; Cornea, Anda; Bush, Eugene; Goulet, Mark T.; Ashton, Wallace T.; Sauer, Daryl R.; Haviv, Fortuna; Greer, Jonathan; Michael Conn, P.

In: Molecular and Cellular Endocrinology, Vol. 272, No. 1-2, 30.06.2007, p. 77-85.

Research output: Contribution to journalArticle

Janovick, JA, Brothers, SP, Cornea, A, Bush, E, Goulet, MT, Ashton, WT, Sauer, DR, Haviv, F, Greer, J & Michael Conn, P 2007, 'Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro', Molecular and Cellular Endocrinology, vol. 272, no. 1-2, pp. 77-85. https://doi.org/10.1016/j.mce.2007.04.012
Janovick, Jo Ann ; Brothers, Shaun P ; Cornea, Anda ; Bush, Eugene ; Goulet, Mark T. ; Ashton, Wallace T. ; Sauer, Daryl R. ; Haviv, Fortuna ; Greer, Jonathan ; Michael Conn, P. / Refolding of misfolded mutant GPCR : Post-translational pharmacoperone action in vitro. In: Molecular and Cellular Endocrinology. 2007 ; Vol. 272, No. 1-2. pp. 77-85.
@article{517d4253326d4c5a843fe1b02210045a,
title = "Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro",
abstract = "All reported GnRH receptor mutants (causing human hypogonadotropic hypogonadism) are misfolded proteins that cannot traffic to the plasma membrane. Pharmacoperones correct misfolding and rescue mutants, routing them to the plasma membrane where they regain function. Because pharmacoperones are often peptidomimetic antagonists, these must be removed for receptor function after rescue; in vivo this necessitates pulsatile pharmacoperone administration. As an antecedent to in vivo studies, we determined whether pharmacoperones need to be present at the time of synthesis or whether previously misfolded proteins could be refolded and rescued. Accordingly, we blocked either protein synthesis or intra-cellular transport. Biochemical and morphological studies using 12 mutants and 10 pharmacoperones representing three different chemical classes show that previously synthesized mutant proteins, retained by the quality control system (QCS), are rescued by pharmacoperones, showing that pharmacoperone administration in vivo likely need not consider whether the target protein is being synthesized at the time of drug administration.",
keywords = "G protein coupled receptor, Hypogonadotropic hypogonadism, Protein folding, Protein trafficking",
author = "Janovick, {Jo Ann} and Brothers, {Shaun P} and Anda Cornea and Eugene Bush and Goulet, {Mark T.} and Ashton, {Wallace T.} and Sauer, {Daryl R.} and Fortuna Haviv and Jonathan Greer and {Michael Conn}, P.",
year = "2007",
month = "6",
day = "30",
doi = "10.1016/j.mce.2007.04.012",
language = "English",
volume = "272",
pages = "77--85",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Refolding of misfolded mutant GPCR

T2 - Post-translational pharmacoperone action in vitro

AU - Janovick, Jo Ann

AU - Brothers, Shaun P

AU - Cornea, Anda

AU - Bush, Eugene

AU - Goulet, Mark T.

AU - Ashton, Wallace T.

AU - Sauer, Daryl R.

AU - Haviv, Fortuna

AU - Greer, Jonathan

AU - Michael Conn, P.

PY - 2007/6/30

Y1 - 2007/6/30

N2 - All reported GnRH receptor mutants (causing human hypogonadotropic hypogonadism) are misfolded proteins that cannot traffic to the plasma membrane. Pharmacoperones correct misfolding and rescue mutants, routing them to the plasma membrane where they regain function. Because pharmacoperones are often peptidomimetic antagonists, these must be removed for receptor function after rescue; in vivo this necessitates pulsatile pharmacoperone administration. As an antecedent to in vivo studies, we determined whether pharmacoperones need to be present at the time of synthesis or whether previously misfolded proteins could be refolded and rescued. Accordingly, we blocked either protein synthesis or intra-cellular transport. Biochemical and morphological studies using 12 mutants and 10 pharmacoperones representing three different chemical classes show that previously synthesized mutant proteins, retained by the quality control system (QCS), are rescued by pharmacoperones, showing that pharmacoperone administration in vivo likely need not consider whether the target protein is being synthesized at the time of drug administration.

AB - All reported GnRH receptor mutants (causing human hypogonadotropic hypogonadism) are misfolded proteins that cannot traffic to the plasma membrane. Pharmacoperones correct misfolding and rescue mutants, routing them to the plasma membrane where they regain function. Because pharmacoperones are often peptidomimetic antagonists, these must be removed for receptor function after rescue; in vivo this necessitates pulsatile pharmacoperone administration. As an antecedent to in vivo studies, we determined whether pharmacoperones need to be present at the time of synthesis or whether previously misfolded proteins could be refolded and rescued. Accordingly, we blocked either protein synthesis or intra-cellular transport. Biochemical and morphological studies using 12 mutants and 10 pharmacoperones representing three different chemical classes show that previously synthesized mutant proteins, retained by the quality control system (QCS), are rescued by pharmacoperones, showing that pharmacoperone administration in vivo likely need not consider whether the target protein is being synthesized at the time of drug administration.

KW - G protein coupled receptor

KW - Hypogonadotropic hypogonadism

KW - Protein folding

KW - Protein trafficking

UR - http://www.scopus.com/inward/record.url?scp=34250172768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250172768&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2007.04.012

DO - 10.1016/j.mce.2007.04.012

M3 - Article

C2 - 17555869

AN - SCOPUS:34250172768

VL - 272

SP - 77

EP - 85

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1-2

ER -